Top Markets
Coin of the day
Aequus Pharmaceuticals Inc. Aequus Pharmaceuticals Inc.

Aequus Pharmaceuticals Inc.

AQS
주식 순위 #39477
Aequus Pharmaceuticals Inc. is a specialized Canadian pharmaceutical company... Aequus Pharmaceuticals Inc. is a specialized Canadian pharmaceutical company dedicated to advancing and commercializing therapeutic solutions. Its core operations span critical areas such as neurology, ophthalmology, and transplantation. The company currently markets a range of products, including Vistitan, an ophthalmic treatment designed to alleviate elevated intraocular pressure in individuals suffering from open-angle glaucoma or ocular hypertension. Another key offering is Tacrolimus IR, an immunosuppressant vital for both preventing and treating acute rejection in organ transplant recipients. Aequus also provides its Evolve line of dry eye products, which target various symptoms associated with dry eye disease and blepharitis, such as discomfort, stinging, burning, and dryness, alongside a preservative-free ophthalmic option. In its development pipeline, Aequus is progressing several innovative candidates. These include Topiramate XR and Oxcarbazepine XR, extended-release oral tablets aimed at epilepsy treatment; AQS1303, a transdermal formulation of pyridoxine/doxylamine developed to combat nausea and vomiting during pregnancy; and AQS1304, a cannabinoid-based therapeutic under investigation for neurological disorders. To support its market reach and innovation, Aequus has forged strategic alliances. These include an agreement with Sandoz Canada, Inc. for the promotion of Vistitan; a partnership with Supernus Pharmaceuticals, Inc. for the marketing of its extended-release anti-epileptic drugs; and a collaboration with Medicom Healthcare Ltd. centered on preservative-free ophthalmic treatments. Established in 2013, Aequus Pharmaceuticals Inc. maintains its corporate headquarters in Vancouver, Canada.
주가
$0.00359455
마지막 동기화: 2025-05-20
시가총액
$476.76K
변동 (1일)
0.44%
변동 (1년)
0.00%
국가
CA
거래 Aequus Pharmaceuticals Inc. (AQS)

카테고리

Aequus Pharmaceuticals Inc. (AQS)의 P/E 비율
2026 기준 P/E 비율 TTM: 0
Aequus Pharmaceuticals Inc.의 최신 재무 보고서와 주가에 따르면 현재 P/E (TTM) 비율은 0입니다. 2026년 말 기준 P/E 비율은 0였습니다.
Aequus Pharmaceuticals Inc.의 P/E 비율 기록 (2026 ~ 2026)
매년 말 P/E 비율
연도 P/E 비율 변화
제공된 날짜에 대한 데이터가 충분하지 않습니다.
유사 기업 또는 경쟁사의 P/E 비율
P/E 비율 읽는 방법

P/E 비율은 회사의 주가와 주당순이익 간의 관계를 측정합니다.
낮지만 양수인 P/E는 현재 가치 대비 높은 수익을 내고 있는 저평가된 기업을 의미합니다. 높은 음수(0에 가까운) P/E는 큰 손실을 나타냅니다.

P/E가 30을 초과하거나 음수인 기업은 일반적으로 '성장주'로 간주되며, 투자자들은 향후 수익성 개선을 기대합니다.

양의 P/E가 10 미만인 기업은 일반적으로 '가치주'로 간주되며, 이미 매우 수익성이 높고 향후 큰 성장은 기대되지 않습니다.